Gilead Sciences (GILD)
169.72
-0.96 (-0.56%)
NASDAQ · Last Trade: Nov 2nd, 12:35 PM EST
News & Press Releases
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including late-breaking data and two oral presentations, along with Gilead-led symposia and community forums, reflect the company’s person-centered approach to advancing scientific discovery and the importance of partnership to help end the HIV epidemic.
By Gilead Sciences, Inc. · Via Business Wire · November 2, 2026
Amgen (AMGN) reports Q3: everything you need to know ahead of earnings
Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp...
Via StockStory · November 1, 2026
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio...
Via StockStory · November 1, 2026
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in Novemberfool.com
The company is having a great year.
Via The Motley Fool · November 1, 2026
Gilead Sciences (NASDAQ:GILD): A Dividend Quality Candidate for Income Investorschartmill.com
Via Chartmill · October 31, 2026
Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Linechartmill.com
Via Chartmill · October 29, 2026
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...
Via StockStory · October 31, 2026
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
By Gilead Sciences, Inc. · Via Business Wire · October 30, 2026
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...
Via StockStory · October 30, 2026
S&P 500 Gap Movers for October 30, 2026chartmill.com
Via Chartmill · October 30, 2026
Gilead (GILD) Q3 2026 Earnings Call Transcriptfool.com
Base business sales surged 16%, marking strongest growth in over a decade.
Via The Motley Fool · October 30, 2026
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026chartmill.com
Via Chartmill · October 30, 2026
What Gilead Sciences (GILD) Said on Its Q3 Earnings Callmarketbeat.com
Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining t
Via MarketBeat · October 29, 2026
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fallchartmill.com
Via Chartmill · October 29, 2026
Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...
Via StockStory · October 29, 2026
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decadeinvestors.com
Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.
Via Investor's Business Daily · October 29, 2026
Gilead Sciences Announces Third Quarter 2026 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026.
By Gilead Sciences, Inc. · Via Business Wire · October 29, 2026
Gilead Sciences earnings: what to look for from GILD
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences...
Via StockStory · October 27, 2026
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?fool.com
BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.
Via The Motley Fool · October 27, 2026
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?fool.com
These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.
Via The Motley Fool · October 25, 2026
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?fool.com
Both of these biotech stocks could be appealing to income investors.
Via The Motley Fool · October 25, 2026
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?fool.com
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.
Via The Motley Fool · October 23, 2026
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.
By Gilead Sciences, Inc. · Via Business Wire · October 22, 2026
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management across these two rare and serious liver diseases.
By Gilead Sciences, Inc. · Via Business Wire · October 22, 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?fool.com
Both of these ETFs look the part, but only one is truly the better buy for investors.
Via The Motley Fool · October 22, 2026